Fifth Third Bancorp’s BioLineRX BLRX Stock Holding History

Fifth Third Bancorp’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-25	Closed	-$114	–	2680
2025 Q2	$114	Buy	+25	New	+$92	﹤0.01%	2543

Other funds holding BLRX

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

NRG

Nemes Rush Group Novi, Michigan $1.05B AUM 30.08% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fifth Third Bancorp's BLRX Position: Q3 2025 in Review

Fifth Third Bancorp sold out of BioLineRX (BLRX) in Q3 2025, closing a stake of 25 shares — an estimated $114 sold.

Fifth Third Bancorp first reported a position in BLRX in Q2 2025 and held it in 1 quarter. The position peaked at $114 in Q2 2025. 14 funds tracked by Wall St. Rank hold BLRX as of Q3 2025.

Fifth Third Bancorp reported no remaining BioLineRX position as of Q3 2025 after selling out during the quarter.
Fifth Third Bancorp sold 25 BioLineRX shares in Q3 2025, an estimated $114.
Fifth Third Bancorp first reported a position in BioLineRX in Q2 2025 and held it in 1 quarter.
Fifth Third Bancorp's BioLineRX position peaked at $114 in Q2 2025.
14 funds tracked by Wall St. Rank held BioLineRX as of Q3 2025.

Based on Fifth Third Bancorp's 13F filing for Q3 2025, filed 7 Nov 2025.